Abstract

Info

Title:: Advances in research on the relationship between 5-hydroxytryptamine and cancer

Author(s):: HUANG Shuting¹; WU Xiaoxue²; MEI Yong³; LI Qinghai³; SONG Mei²; HE Weiling³; 4; 1.College of Public Health,Sun Yat-sen University,Guangdong Guangzhou 510080,China;2.Institute of Precision Medicine,the First Affiliated Hospital,Sun Yat-sen University,Guangdong Guangzhou 510000,China;3.Department of Gastrointestinal Surgery,the First Affiliated Hospital,Sun Yat-sen University,Guangdong Guangzhou 510080,China;4.Department of Gastrointestinal Surgery,Xiang'an Hospital of Xiamen University,Fujian Xiamen 361000,China.

Keywords:: 5-hydroxytryptamine; 5-HT receptors; cancer therapeutic targets

PACS:: R730.5

DOI:: 10.3969/j.issn.1672-4992.2023.18.031

Abstract:: The role of 5-hydroxytryptamine (5-HT) as a neurotransmitter in the central nervous system and a motor regulator in the gastrointestinal tract has been well established,and its role in the occurrence of various cancers is under investigation.5-HT can activate the PI3K/AKT pathway,MAPK pathway,JAK/STAT pathway,Wnt pathway through different receptors and mechanisms,promote cell proliferation and migration,and mediate anti-tumor immune responses.A variety of enzymes in its metabolic pathways are highly expressed in a variety of tumors,which is a potential target for tumor treatment.In recent years,metabolic disorders of 5-HT have been found in a variety of tumors,including colorectal cancer,liver cancer,pancreatic cancer,ovarian cancer,prostate cancer,breast cancer,etc.Therefore,the research on 5-HT metabolism is of great significance in tumor treatment.This review systematically summarizes the relationship between 5-HT and cancer and the research progress,and elucidates the scientific basis for 5-HT as a potential new cancer treatment target,which provides new ideas for the development of drugs targeting the enzymes,metabolites or receptors of 5-HT metabolic pathway.

References:

[1] JONES LA,SUN EW,MARTIN AM,et al.The ever-changing roles of serotonin［J］.Int J Biochem Cell Biol,2020,125:105776.
[2] CHEUNG A,KONNO K,IMAMURA Y,et al.Neurexins in serotonergic neurons regulate neuronal survival,serotonin transmission,and complex mouse behaviors［J］.Elife,2023,12:e85058.
[3] OKATY BW,COMMONS KG,DYMECKI SM.Embracing diversity in the 5-HT neuronal system［J］.Nat Rev Neurosci,2019,20(7):397-424.
[4] LIU N,SUN S,WANG P,et al.The mechanism of secretion and metabolism of gut-derived 5-hydroxytryptamine［J］.Int J Mol Sci,2021,22(15):7931.
[5] CHEN JR,HUANG MS,LEE YC,et al.Potential clinical value of 5-hydroxytryptamine receptor 3C as a prognostic biomarker for lung cancer［J］.J Oncol,2021,2021:1901191.
[6] QUINTERO-VILLEGAS A,VALDS-FERRER SI.Role of 5-HT(7) receptors in the immune system in health and disease［J］.Mol Med,2019,26(1):2.
[7] ROTH W,ZADEH K,VEKARIYA R,et al.Tryptophan metabolism and gut-brain homeostasis［J］.Int J Mol Sci,2021,22(6):2973.
[8] KARMAKAR S,LAL G.Role of serotonin receptor signaling in cancer cells and anti-tumor immunity［J］.Theranostics,2021,11(11):5296-5312.
[9] DE DEURWAERDRE P,DI GIOVANNI G.Serotonin in health and disease［J］.Int J Mol Sci,2020,21(10):3500.
[10] FOUQUET G,COMAN T,HERMINE O,et al.Serotonin,hematopoiesis and stem cells［J］.Pharmacol Res,2019,140:67-74.
[11] SHARP T,BARNES NM.Central 5-HT receptors and their function;present and future［J］.Neuropharmacology,2020,177:108155.
[12] LAYUNTA E,BUEY B,MESONERO JE,et al.Crosstalk between intestinal serotonergic system and pattern recognition receptors on the microbiota-gut-brain axis［J］.Front Endocrinol (Lausanne),2021,12:748254.
[13] LICHTENSTERN CR,NGU RK,SHALAPOUR S,et al.Immunotherapy,inflammation and colorectal cancer［J］.Cells,2020,9(3):618.
[14] ZENG C,CHEN Y.HTR1D,TIMP1,SERPINE1,MMP3 and CNR2 affect the survival of patients with colon adenocarcinoma［J］.Oncol Lett,2019,18(3):2448-2454.
[15] LI T,FU B,ZHANG X,et al.Overproduction of gastrointestinal 5-HT promotes colitis-associated colorectal cancer progression via enhancing NLRP3 inflammasome activation［J］.Cancer Immunol Res,2021,9(9):1008-1023.
[16] ZHU P,LU T,CHEN Z,et al.5-hydroxytryptamine produced by enteric serotonergic neurons initiates colorectal cancer stem cell self-renewal and tumorigenesis［J］.Neuron,2022,110(14):2268-2282.
[17] SUI H,XU H,JI Q,et al.5-hydroxytryptamine receptor (5-HT1DR) promotes colorectal cancer metastasis by regulating Axin1/β-catenin/MMP-7 signaling pathway［J］.Oncotarget,2015,6(28):25975-25987.
[18] KANNEN V,BADER M,SAKITA JY,et al.The dual role of serotonin in colorectal cancer［J］.Trends Endocrinol Metab,2020,31(8):611-625.
[19] LI Z,DING B,ALI M,et al.Dual effect of tryptamine on prostate cancer cell growth regulation:a pilot study［J］.Int J Mol Sci,2022,23(19):11087.
[20] SAKITA JY,BADER M,SANTOS ES,et al.Serotonin synthesis protects the mouse colonic crypt from DNA damage and colorectal tumorigenesis［J］.J Pathol,2019,249(1):102-113.
[21] BATTAGLIN F,JAYACHANDRAN P,STRELEZ C,et al.Neurotransmitter signaling:a new frontier in colorectal cancer biology and treatment［J］.Oncogene,2022,41(43):4769-4778.
[22] YE D,XU H,XIA H,et al.Targeting SERT promotes tryptophan metabolism:mechanisms and implications in colon cancer treatment［J］.J Exp Clin Cancer Res,2021,40(1):173.
[23] ZUO X,CHEN Z,CAI J,et al.5-hydroxytryptamine receptor 1D aggravates hepatocellular carcinoma progression through FoxO6 in AKT-dependent and independent manners［J］.Hepatology,2019,69(5):2031-2047.
[24] BHAGAVATHULA AS,WOOLF B,RAHMANI J,et al.Selective serotonin reuptake inhibitor use and the risk of hepatocellular carcinoma:a systematic review and dose-response analysis of cohort studies with one million participants［J］.Eur J Clin Pharmacol,2022,78(4):547-555.
[25] SCHNEIDER MA,HEEB L,BEFFINGER MM,et al.Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models［J］.Sci Transl Med,2021,13(611):c8188.
[26] WU KK.Cytoguardin:a tryptophan metabolite against cancer growth and metastasis［J］.Int J Mol Sci,2021,22(9)：4490.
[27] KLEIN AP.Pancreatic cancer epidemiology:understanding the role of lifestyle and inherited risk factors［J］.Nat Rev Gastroenterol Hepatol,2021,18(7):493-502.
[28] PETERS M,MEIJER C,FEHRMANN R,et al.Serotonin and dopamine receptor expression in solid tumours including rare cancers［J］.Pathol Oncol Res,2020,26(3):1539-1547.
[29] JIANG SH,LI J,DONG FY,et al.Increased serotonin signaling contributes to the Warburg effect in pancreatic tumor cells under metabolic stress and promotes growth of pancreatic tumors in mice［J］.Gastroenterology,2017,153(1):277-291.
[30] KRUK J,ABOUL-ENEIN BH,BERNSTEIN J,et al.Psychological stress and cellular aging in cancer:a meta-analysis［J］.Oxid Med Cell Longev,2019,2019:1270397.
[31] CUI B,PENG F,LU J,et al.Cancer and stress:NextGen strategies［J］.Brain Behav Immun,2021,93:368-383.
[32] QIN X,LI J,WANG S,et al.Serotonin/HTR1E signaling blocks chronic stress-promoted progression of ovarian cancer［J］.Theranostics,2021,11(14):6950-6965.
[33] BALAKRISHNA P,GEORGE S,HATOUM H,et al.Serotonin pathway in cancer［J］.Int J Mol Sci,2021,22(3):1268.
[34] ALWHAIBI A,ALSANEA S,ALMADI B,et al.Androgen deprivation therapy and depression in the prostate cancer patients: review of risk and pharmacological management［J］.Aging Male,2022,25(1):101-124.
[35] CHEN L,JI Y,LI A,et al.High-throughput drug screening identifies fluoxetine as a potential therapeutic agent for neuroendocrine prostate cancer［J］.Front Oncol,2023,13:1085569.
[36] DIZEYI N,BJARTELL A,NILSSON E,et al.Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines［J］.Prostate,2004,59(3):328-336.
[37] WU JB,SHAO C,LI X,et al.Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis［J］.J Clin Invest,2014,124(7):2891-2908.
[38] WU JB,LIN TP,GALLAGHER JD,et al.Monoamine oxidase A inhibitor-near-infrared dye conjugate reduces prostate tumor growth［J］.J Am Chem Soc,2015,137(6):2366-2374.
[39] DIZEYI N,HEDLUND P,BJARTELL A,et al.Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines［J］.Urol Oncol,2011,29(4):436-445.
[40] YU S,LI W,TANG L,et al.Depression in breast cancer patients:Immunopathogenesis and immunotherapy［J］.Cancer Lett,2022,536:215648.
[41] SARROUILHE D,CLARHAUT J,DEFAMIE N,et al.Serotonin and cancer:what is the link［J］.Curr Mol Med,2015,15(1):62-77.
[42] SARROUILHE D,MESNIL M.Serotonin and human cancer:A critical view［J］.Biochimie,2019,161:46-50.
[43] PAI VP,MARSHALL AM,HERNANDEZ LL,et al.Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival［J］.Breast Cancer Res,2009,11(6):R81.
[44] OLFATI Z,RIGI G,VASEGHI H,et al.Evaluation of serotonin receptors (5HTR2A and 5HTR3A) mRNA expression changes in tumor of breast cancer patients［J］.Med J Islam Repub Iran,2020,34:99.
[45] YIN L,DUAN JJ,BIAN XW,et al.Triple-negative breast cancer molecular subtyping and treatment progress［J］.Breast Cancer Res,2020,22(1):61.
[46] WAKS AG,WINER EP.Breast cancer treatment:a review［J］.JAMA,2019,321(3):288-300.
[47] BIANCHINI G,DE ANGELIS C,LICATA L,et al.Treatment landscape of triple-negative breast cancer - expanded options,evolving needs［J］.Nat Rev Clin Oncol,2022,19(2):91-113.
[48] LI RQ,ZHAO XH,ZHU Q,et al.Exploring neurotransmitters and their receptors for breast cancer prevention and treatment［J］.Theranostics,2023,13(3):1109-1129.
[49] FUKUYAMA K,MOTOMURA E,OKADA M.Therapeutic potential and limitation of serotonin type 7 receptor modulation［J］.Int J Mol Sci,2023,24(3):2070.
[50] CINAR V,HAMURCU Z,GULER A,et al.Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1［J］.Breast Cancer,2022,29(6):1106-1120.

Advances in research on the relationship between 5-hydroxytryptamine and cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Info

References:

Memo

Common functions

Navigate

Tools

Statistics